Biblio

33557 resultats trouvés
P
Castelli J., Feuvret L., Haoming Q.C, Biau J., Jouglar E., Berger A., Truc G., F. Gutierrez L, Morandi X., Le Reste P.J et al..  2016.  Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. JOURNAL OF NEURO-ONCOLOGY. 129:85-92.
Tauziede-Espariat A, Bresson D, Polivka M, Bouazza S, Labrousse F, Aronica E, Pretet J-L, Projetti F, Herman P, Salle H et al..  2016.  Prognostic and Therapeutic Markers in Chordomas: A Study of 287 Tumors. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. 75:111-120.
Herr N, Nicod J-M, Varnier C.  2014.  Prognostic Decision Making to Extend a Platform Useful Life under Service Constraint. 2014 IEEE CONFERENCE ON PROGNOSTICS AND HEALTH MANAGEMENT (PHM).
Herr N, Nicod J-M, Varnier C.  2014.  Prognostic Decision Making to Extend a Platform Useful Life under Service Constraint. 2014 IEEE CONFERENCE ON PROGNOSTICS AND HEALTH MANAGEMENT (PHM).
Taieb J, Zaanan A, Le Malicot K, Julie C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G et al..  2016.  Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab A Post Hoc Analysis of the PETACC-8 Trial. JAMA ONCOLOGY. 2:643-652.
Aparicio T., Bouche O., Francois E., Maillard E., Kirscher S., Taieb J., Etienne P-L., Faroux R., F. Akouz K, F. Hajbi E et al..  2016.  Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20. ANNALS OF ONCOLOGY. 27
Manceau G, Voron T, Mege D, Bridoux V, Lakkis Z, Venara A, Beyer-Berjot L, Abdalla S, Sielezneff I, Lefevre JH et al..  2019.  Prognostic factors and patterns of recurrence after emergency management for obstructing colon cancer: multivariate analysis from a series of 2120 patients. LANGENBECKS ARCHIVES OF SURGERY. 404:717-729.
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, Schinagl D, Oei B, Rodenhuis CC, Horiot J-C et al..  2017.  Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial A Randomized Clinical Trial. JAMA ONCOLOGY. 3:42-48.
Audureau E, Chivet A, Ursu R, Corns R, Metellus P, Noel G, Zouaoui S, Guyotat J, Le Reste P-J, Faillot T et al..  2018.  Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. JOURNAL OF NEURO-ONCOLOGY. 136:565-576.
Gravis G, Boher J-M, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B et al..  2015.  Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. EUROPEAN UROLOGY. 68:196-204.
Touchefeu Y., Guimbaud R., Louvet C., Dahan L., Samalin E., Barbier E., Le Malicot K., Cohen R., Gornet J.M, Aparicio T. et al..  2019.  Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. GASTRIC CANCER. 22:577-586.
Mekhail C, Chouk M, Prati C, Wendling D, Verhoeven F.  2020.  Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 13:505-519.
Mekhail C, Chouk M, Prati C, Wendling D, Verhoeven F.  2020.  Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 13:505-519.
Vincent L., Jankowski C., Ouldamer L., Ballester M., Bendifallah S., Bolze P.A, Akladios C., Costaz H., Lavoue V, Canlorbe G. et al..  2020.  Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group. EJSO. 46:1689-1696.
Vincent L, Jankowski C, Ouldamer L, Ballester M, Bendifallah S, Bolze P-A, Akladios C, Costaz H, Lavoue V, Uzan C et al..  2019.  Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery. JOURNAL OF CLINICAL ONCOLOGY. 37
Marshall EM, Bertaut A, Desmoulins I, Darut-Jouve A, Ponnelle T, Poillot M-L, Beltjens F, Arveux P.  2017.  Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study. BREAST JOURNAL. 23:138-145.
Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Delgado MBeso, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R et al..  2019.  Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. LIVER INTERNATIONAL. 39:136-146.
Benjamin H., Florence M., Alice C., Valerie L.C, Marie-Lorraine C., Cyrille H., Xavier L., Gerald M., Lionel K., Murielle R. et al..  2014.  PROGNOSTIC HETEROGENEITY AMONG HIGH RISK MULTIPLE MYELOMA PATIENTS (T(4-14) AND DEL17P) ACCORDING TO ADDITIONAL CYTOGENETIC ABNORMALITIES, THE IFM EXPERIENCE. HAEMATOLOGICA. 99:495.
Benjamin H., Florence M., Alice C., Valerie L.C, Marie-Lorraine C., Cyrille H., Xavier L., Gerald M., Lionel K., Murielle R. et al..  2014.  PROGNOSTIC HETEROGENEITY AMONG HIGH RISK MULTIPLE MYELOMA PATIENTS (T(4-14) AND DEL17P) ACCORDING TO ADDITIONAL CYTOGENETIC ABNORMALITIES, THE IFM EXPERIENCE. HAEMATOLOGICA. 99:495.
Benjamin H., Florence M., Alice C., Valerie L.C, Marie-Lorraine C., Cyrille H., Xavier L., Gerald M., Lionel K., Murielle R. et al..  2014.  PROGNOSTIC HETEROGENEITY AMONG HIGH RISK MULTIPLE MYELOMA PATIENTS (T(4-14) AND DEL17P) ACCORDING TO ADDITIONAL CYTOGENETIC ABNORMALITIES, THE IFM EXPERIENCE. HAEMATOLOGICA. 99:495.
Cadranel J, Quoix E, Duruisseaux M, Friard S, Wislez M, Danie C, Fabre E, Madroszyk A, Westeel V, Merle P et al..  2017.  Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study. JOURNAL OF THORACIC ONCOLOGY. 12:S957-S958.
Cadranel J, Quoix E, Duruisseaux M, Friard S, Wislez M, Danie C, Fabre E, Madroszyk A, Westeel V, Merle P et al..  2017.  Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study. JOURNAL OF THORACIC ONCOLOGY. 12:S957-S958.
Santarpino G, Nicolini F, De Feo M, Dalen M, Fischlein T, Perrotti A, Reichart D, Gatti G, Onorati F, Franzese I et al..  2018.  Prognostic Impact of Asymptomatic Carotid Artery Stenosis in Patients Undergoing Coronary Artery Bypass Grafting. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY. 56:741-748.
Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, Ward KN, Cordonnier C, de la Camara R, Averbuch D, Knelange N et al..  2019.  Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. BONE MARROW TRANSPLANTATION. 54:2060-2071.
Biancari F, Dalen M, Ruggieri VG, Demal T, Gatti G, Onorati F, Faggian G, Rubino AS, Maselli D, Gherli R et al..  2018.  Prognostic Impact of Multiple Prior Percutaneous Coronary Interventions in Patients Undergoing Coronary Artery Bypass Grafting. JOURNAL OF THE AMERICAN HEART ASSOCIATION. 7:e010089.

Pages